
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical has established a strong position in the ophthalmic surgical product segment, generating the majority of its sales from its Implantable Collamer lenses (ICL) and intraocular lenses (IOL) used in refractive and cataract surgeries, respectively. Despite competition from larger firms such as Novartis/Alcon, Abbott/AMO, and Bausch & Lomb, Staar Surgical's innovative product offerings and specialization within the niche market of implantable lenses demonstrate potential for growth. The company's focus on advanced ophthalmic technologies positions it well to capitalize on increasing demand in eye care treatments, reinforcing a positive outlook for its financial performance moving forward.
Bears say
Staar Surgical faces potential challenges due to increased competition from larger manufacturers, which could adversely affect its gross margins if these competitors engage in price competition. Additionally, ongoing government efforts to manage healthcare costs may lead to a decline in reimbursement rates for intraocular lenses (IOLs), further threatening the company's financial performance. Lastly, any failure to secure regulatory approval for its product pipeline could hinder Staar Surgical's ability to expand its implantable Collamer lens (ICL) market, limiting future growth prospects.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares